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Abstract: Oxidative stress linked to vascular damage plays an important role in the pathogenesis
of systemic sclerosis (SSc). Indeed, vascular damage at nailfold capillaroscopy in patients with
Raynaud’s Phenomenon (RP) is a major risk factor for the development of SSc together with the
presence of specific autoantiobodies. Here, we investigated the effects of the phosphodiesterase
type 5 inhibitor (PDE5i) sildenafil, currently used in the management of RP, in modulating the
proinflammatory response of dermal fibroblasts to oxidative stress in vitro. Human fibroblasts
isolated from SSc patients and healthy controls were exposed to exogenous reactive oxygen species
(ROS) (100 µM H2O2), in the presence or absence of sildenafil (1 µM). Treatment with sildenafil
significantly reduced dermal fibroblast gene expression and cellular release of IL-6, known to play
a central role in the pathogenesis of tissue damage in SSc and IL-8, directly induced by ROS. This
reduction was associated with suppression of STAT3-, ERK-, NF-κB-, and PKB/AKT-dependent
pathways. Our findings support the notion that the employment of PDE5i in the management of
RP may be explored for its efficacy in modulating the oxidative stress-induced proinflammatory
activation of dermal fibroblasts in vivo and may ultimately aid in the prevention of tissue damage
caused by SSc.
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1. Introduction
Systemic sclerosis (SSc) is a rare systemic disease characterized by autoimmune-driven
inflammation, vasculopathy, and tissue fibrosis affecting the skin and internal organs. Fibrosis
is the most prominent clinical feature of SSc and the major cause of mortality [1]. This process is led by
excessive fibroblast activation and extra-cellular matrix deposition, which in turn causes multi-organ
dysfunction [2]. Data from several groups demonstrated the pivotal role of oxidative stress in SSc
pathogenesis and internal organ fibrogenesis, highlighting the interplay of an altered redox-state and
abnormal activation of pro-inflammatory pathways [3,4]. Indeed, lymphocytes, T helper cells (i.e., 1
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and 17), B-cell activation, and proinflammatory cytokines participate in the tissue damage caused by
SSc through the overproduction of reactive oxygen species (ROS) [5]. In this regard, multiple lines of
evidence indicate that interleukin (IL)-8 and IL-6 are critical in SSc pathogenesis [5–7]. Both interleukins
are normally elevated in the blood of SSc patients, and their production/secretion is strongly sustained
by immune cells and fibroblasts [5]. Importantly, monoclonal antibody-mediated blocking of the IL-6
pathway has been explored and has shown some benefit in preventing progression of lung fibrosis in
SSc [8–11].
Two independent studies have shown that the phosphodiesterase inhibitors (PDEi) inhibit
production and release of IL-6 and IL-8 in human peripheral blood leukocytes and cardiomyocytes
subjected to inflammatory stimuli [12,13].
Sildenafil is a PDE5i routinely used for the management of Raynaud’s phenomenon, which is in
turn the main clinical risk factor for developing SSc in people with specific Antinuclear Antibodies
(ANA). Here, we set out to determine the effects of sildenafil on gene expression and release of IL-6
and IL-8 in cell cultures of human dermal fibroblasts (Hfb), which are thought to be among the key
cellular elements in the pathogenesis of SSc.
2. Results
2.1. Sildenafil Inhibited Secretion and Gene Transcription of IL-6 and IL-8 Induced by Hydrogen Peroxide
H2O2 treatment induced strong release of IL-8 in dermal fibroblasts as expected (99.3 ± 3.5 vs.
31.4 ± 0.3 pg/mL basal levels) (Figure 1A). Dermal fibroblasts from SSc had a similar basal level but
showed more than two-fold higher induction following H2O2 treatment (236.1 ± 12.0 pg/mL, p < 0.01).
Pre-treatment with sildenafil suppressed the aberrant response of SSc cells, resulting in levels similar
to healthy control fibroblasts (124.1 ± 28.0 pg/mL). Interestingly, sildenafil did not affect basal levels
or the response of healthy control fibroblasts to H2O2 (Figure 1A). These results were paralleled at
the gene transcription level. In particular, the pro-oxidant environment induced significant increases
in IL-8 gene expression in healthy (control (c) vs. H2O2: IL-8, 0.1 ± 0.0 vs. 0.3 ± 0.0, p < 0.01) or
in SSc fibroblasts (c vs. H2O2: IL-8, 0.1 ± 0.0 vs. 0.4 ± 0.2, p < 0.01). The concomitant presence of
sildenafil in the culture medium reduced the effects of H2O2 on the gene expression of IL-8 in both
experimental groups, healthy (H2O2 + S: 0.2 ± 0.2, p > 0.05) and SSc fibroblasts (H2O2 + S: 0.2 ± 0.1,
p < 0.05). The presence of sildenafil did not produce any significant change in IL-8 expression in both
cell lines (Figure 1B).
Supernatants from SSc fibroblasts secreted almost 10 times more IL-6 than healthy controls under
basal conditions (1089.0 ± 91.0 pg/mL vs. 134.7 ± 3.7 pg/mL in healthy control fibroblasts, p < 0.01).
The difference remained significant following exposure to H2O2, with the concentration rising to
351.8 ± 8.6 pg/mL for healthy control cells and 2148.0 ± 59.3 pg/mL for SSc cells (p < 0.01, Figure 1C).
The pre-treatment with sildenafil reduced IL-6 secretion in both experimental groups (healthy:
233.0 ± 10.2 pg/mL; SSc: 1043.0 ± 60.0 pg/mL). Interestingly, sildenafil did not affect the basal levels of
IL-6 secretion in either experimental group (Figure 1A,B). At the gene expression level, IL-6 showed
increased basal levels in SSc fibroblasts, consistent with previous reports [14] (healthy vs. SSc: 0.1 ± 0.0
vs. 0.8 ± 0.4, p < 0.05) (Figure 1D).
The exposure to H2O2 induced a significant increase in IL-6 transcripts in both healthy (c vs.
H2O2: 0.11 ± 0.02 vs. 0.3 ± 0.1, p < 0.05) and SSc fibroblasts (c vs. H2O2: 0.8 ± 0.4 vs. 1.5 ± 0.6,
p < 0.01). Similar to IL-8, the presence of sildenafil in the culture medium completely inhibited the
effect of ROS on IL-6 gene expression in SSc fibroblasts (p > 0.05). Interestingly sildenafil induced a
slight but statistically significant increase in IL-6 expression in fibroblasts from healthy subjects (c vs. S:
0.11 ± 0.02 vs. 0.19 ± 0.03, p < 0.05) (Figure 1D).
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Figure 1. Supernatants (A,C) and RNAs extracted (B,D) from human healthy (black columns) and SSc 
(grey columns) fibroblast cultures exposed to H2O2 (100 µM, 24 h) with or without a pre-treatment 
with sildenafil (1 µM) were analyzed for IL-6 and IL-8 contents. Data are presented as the means ± 
SEM (n = 3). Statistical significance was determined using ANOVA with Bonferroni’s post-hoc test. * 
p < 0.05 and ** p < 0.01 vs. relative control within group; # p < 0.05 and ## p < 0.01 vs. corresponding 
treatment between groups; § p < 0.05; §§ p < 0.01. c, control group; S, sildenafil; NS, not significant. 
2.2. Sildenafil Suppressed the Activation of Intracellular Pathways Induced by the Pro-Oxidant Condition in 
Healthy and SSc Fibroblasts 
Given the effects observed at the gene expression level, we set out to evaluate the effect of 
sildenafil on the intracellular signaling pathways known to be activated by ROS, specifically the 
phosphorylation/activation status of STAT3, NF-κB, ERK1/2, and AKT in both healthy and SSc cells. 
In healthy fibroblasts, the pro-oxidant condition induced a 40% increase in p-ERK/ERK (1.4 ± 0.1, p < 
0.05) and a 30% increase in p-STAT3/STAT3 (1.3 ± 0.0, p < 0.05), whereas no differences were observed 
for p-AKT/AKT and p-NF-κB/NF-κB (p > 0.05) (Figure 2A–F). Treatment with sildenafil prevented 
this upregulation, with levels of p-STAT3/STAT3 and p-ERK/ERK similar to basal values (Figure 2A, 
2C and 2F). Upon the same pro-oxidant conditions, SSc fibroblasts showed a much greater response 
in all markers analyzed, with a 320% increase in p-STAT3/STAT3 (3.2 ± 0.2, p < 0.05) and 340% increase 
in p-AKT/AKT (3.4 ± 0.3, p < 0.05). Most interestingly, p-NF-κB/NF-κB, which was not affected in 
healthy cells, showed a 500% increase (51.0 ± 14.8, p <.05) while p-ERK/ERK was also significantly 
upregulated (60% increase; 1.6 ± 0.1, p < 0.05) (Figure 2B–F). Despite the markedly increased response, 
treatment with sildenafil reduced the level of almost all protein markers. Specifically, p-
STAT3/STAT3 and p-ERK/ERK were completely suppressed (Figure 2A–C,F), whereas pAKT/AKT 
and p-NF-κB/NF-κB were significantly reduced but remained significantly high compared to either 
unstimulated conditions or the healthy control group (Figure 2A,B,D,E). 
Figure 1. Supernatants (A,C) and RNAs extracted (B,D) from human healthy (black columns) and SSc
(grey columns) fibroblast cultures exposed to H2O2 (100 µM, 24 h) with or without a pre-treatment with
sildenafil (1 µM) were analyzed for IL-6 and IL-8 contents. Data are presented as t e means ± SEM
(n = 3). Statistical significance w s determined using ANOVA with Bonferroni’s post-hoc test. * p < 0.05
and ** p < 0.01 v . relative control within group; # p < 0.05 and ## p < 0.01 vs. corresponding treatment
between groups; § p < 0.05; §§ p < 0.01. c, control group; S, sildenafil; NS, not significant.
2.2. Sildenafil Suppressed the Activation of Intracellular Pathways Induced by the Pro-Oxidant Condition in
Healthy and SSc Fibroblasts
Given the effects observed at the gene expression level, we set out to evaluate the effect of
sildenafil on the intracellular signaling pathways known to be activated by ROS, specifically the
phosphorylation/activation status of STAT3, NF-κB, ERK1/2, and AKT in both healthy nd SSc cells. In
healthy fibroblasts, the pro-oxidant condition induced a 40% increase in p-ERK/ERK (1.4 ± 0.1, p < 0.05)
and a 30% increase in p-STAT3/STAT3 (1.3 ± 0.0, p < 0.05), whereas no differences were observed for
p-AKT/AKT and p-NF-κB/NF-κB (p > 0.05) (Figure 2A–F). Treatment with sildenafil prevented this
upregulation, with levels of p-STAT3/STAT3 and p-ERK/ERK similar to basal values (Figure 2A,C,F).
Upon the same pro-oxidant conditions, SSc fibroblasts showed a much greater response in all markers
analyzed, with a 320% increase in p-STAT3/STAT3 (3.2 ± 0.2, p < 0.05) and 340% increase in p-AKT/AKT
(3.4 ± 0.3, p < 0.05). Most interestingly, p-NF-κB/NF-κB, which was not affected in healthy cells,
showed a 500% increase (51.0 ± 14.8, p < 0.05) while p-ERK/ERK was also significantly upregulated
(60% increase; 1.6 ± 0.1, p < 0.05) (Figure 2B–F). Despite the markedly increased response, treatment
with sildenafil reduced the level of almost all protein markers. Specifically, p-STAT3/STAT3 and
p-ERK/ERK were completely suppressed (Figure 2A–C,F), whereas pAKT/AKT and p-NF-κB/NF-κB
were significantly reduced but remained significantly high compared to either unstimulated con itions
or th healthy control group (Figure 2A,B,D,E).
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Figure 2. Representative western blot images of proteins analyzed in (A) healthy and (B) SSc 
fibroblasts. Proteins extracted from human healthy (black columns) and SSc (grey columns) 
fibroblasts exposed to H2O2 (100 µM, 24 h) with or without a pre-treatment with S (1 µM) were 
immunoblotted with antibodies against the total and phosphorylated form of (C) STAT3, (D) AKT, 
(E) NF-κB, and (F) ERK. Bars of the histogram show the ratio between the total and phosphorylated 
form of protein targets. Statistical significance was determined using ANOVA with Bonferroni’s post-
hoc test. The dotted line indicates control levels. * p < 0.05 vs. relative control within group; # p < 0.05 
vs. corresponding treatment between groups; § p < 0.05. S, sildenafil. 
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used to treat erectile dysfunction, Raynaud’s phenomenon, and pulmonary arterial hypertension 
[15]. PDE5 is a group of ubiquitously present enzymes that hydrolyze cyclic guanosine 
monophosphate (cGMP) to its inactive form GMP. This cyclic nucleotide plays a prominent role in 
the regulation of important cellular functions, and PDE5i can therefore elicit a variety of effects 
[16,17]. The capacity of PDE5i to inhibit cytokine release has been already observed [12,13]. In 
particular, sildenafil has been shown to have an immunomodulating ability in human immune cells 
and cardiomyocytes subjected to inflammatory stimuli [12,13]. However, to date, this potential 
mechanism of action has never been explored in SSc. In this study, we showed for the first time that 
the PDE5i sildenafil exerts an inhibitory effect on IL-6 and IL-8 gene expression and is released into 
the culture medium of SSc fibroblasts exposed to ROS. Numerous reports have shown that both IL-6 
and IL-8 levels are elevated in culture supernatants of dermal fibroblasts and serum from patients 
with SSc [10,14]. Consistent with these findings, we observed that SSc fibroblasts cultured in a pro-
Figure 2. Representative western blot images of proteins analyzed in (A) healthy and (B) SSc fibroblasts.
Proteins extracted from human healthy (black columns) and SSc (grey columns) fibroblasts exposed
to H2O2 (100 µM, 24 h) with or without a pre-treatment with S (1 µM) were immunoblotted with
anti odies against the total and phosphorylated form of (C) STAT3, (D) AKT, (E) NF-κB, and (F) ERK.
Bars of the histogram show the ratio between the total and phosphorylated form of protein targets.
Statistical significance was determined using ANOVA with Bonferroni’s post-hoc test. The dotted
line indicates control levels. * p < 0.05 vs. relative control within group; # p < 0.05 vs. corresponding
treatment between groups; § p < 0.05. S, sildenafil.
3. Discussion
Sildenafil belongs to the class of drugs inhibiting phosphodiesterase type 5 (PDE5i) commonly
used to treat erectile dysfunction, Raynaud’s phenomenon, and pulmonary arterial hypertension [15].
PDE5 is a group of ubiquitously present enzymes that hydrolyze cyclic guanosine monophosphate
(cGMP) to i s inactive form GMP. This cyclic nucleotide plays a prominent role in th regulation of
important cellul r functions, and PDE5i can therefore elicit a variety of effects [16,17]. The capacity of
PDE5i t in ibit cytokine release has been already observed [12,13]. In particular, sildenafil has been
shown to have an i munomodulating ability in human immune cells and cardiomyocytes subject d
to inflammatory stimuli [12,13]. However, to date, this potential mechanism of action has never been
explored in SSc. In this study, we showed for the first time that the PDE5i sildenafil exerts an inhibitory
effect on IL-6 and IL-8 gene expression and is released into the culture medium of SSc fibroblasts
exposed to ROS. Numerous reports have shown that both IL-6 and IL-8 levels are elevated in culture
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supernatants of dermal fibroblasts and serum from patients with SSc [10,14]. Consistent with these
findings, we observed that SSc fibroblasts cultured in a pro-oxidant environment showed a significant
increase not only in IL-6 and IL-8 gene expression, but also their secretion in the medium. It remains
to be investigated whether this could be the result of persistent exposure to pro-oxidants and/or of
the reduced antioxidant capacity of these cells [9]. Interestingly, sildenafil did not show effects on
IL-8 secretion in healthy fibroblasts. In a previous study, performed in patients affected by diabetic
cardiomyopathy, we showed that sildenafil could counteract IL-8 release in consequence of a “cut-off”
value [13]. Particularly, only patients with a circulating cytokine level above this “cut-off” were
responsive to sildenafil treatment with a significant decrease of the chemokine. By contrast, patients
with IL-8 below the “cut-off” value were not sensitive to this PDE5i. It is likely that the IL-8 level in
healthy fibroblasts was not sufficient to reach the cut-off value, determining a different sensitivity
to sildenafil.
As suggested by numerous authors, IL-6 and IL-8 may have a direct effect on regulating
tissue fibrosis and endothelial damage [14]. In particular, IL-6 is a pleiotropic pro-inflammatory
cytokine capable of stimulating SSc fibroblasts to differentiate and proliferate, causing collagen
overproduction and fibrosis [6]. IL-8 is a chemoattractant cytokine responsive to oxidative stress that
unlike others has distinct target specificity for neutrophils [18]. The persistent neutrophil activation
determines neutrophils accumulation in different body districts (e.g., lung), promoting the genesis
of interstitial fibrosis, which is one of the most dreaded clinical manifestations of SSc [7,19]. Indeed,
a neutrophil-derived gene signature has been shown to be one of the top discriminants in SSc vs.
healthy control blood and a major biological marker of clinical improvement [20]. To begin to
dissect the potential mechanism by which sildenafil can modulate IL-8 and IL-6 expression, we
analyzed the modulation of proteins such as STAT3, ERK, NF-κB, and PKB/AKT, known to be involved
in ROS-mediated signaling. Firstly, we observed a greater modulation of these molecules in SSc
compared with healthy fibroblasts, supporting the already proposed notion that SSc fibroblasts may
have a reduced ability to counteract the redox-balance [3,21]. Importantly, the presence of sildenafil
significantly reduced the phosphorylation levels of these proteins. We believe that, despite not offering
a complete explanation, these initial observations do inform and warrant future studies aimed to
define the molecular mechanisms underlying this novel biological effect of sildenafil. In this sense,
it would be worth exploring the extent to which this effect is directly mediated by cyclic nucleotide
hydrolysis inhibition or by independently elevating levels of cAMP and cGMP or modulating ion
channels in tissue fibroblasts [22]. In conclusion, we believe that our study, although in vitro and
on a limited set of samples, has a strong potential impact. Sildenafil is one of the commonly used
drugs in the management of Raynaud’s phenomenon, and given the epidemiological observations
strongly indicating that patients with Raynaud’s phenomenon and ANA are at high risk of developing
SSc, the dissection of the mechanisms underlying the PDE5i-induced modulation of proinflammatory
and profibrotic cytokines following ROS may pave the way to extending the scope of treatment with
sildenafil in patients at risk of developing SSc from simple management of Raynaud’s phenomenon to
a pre-disease-modifying agent.
4. Materials and Methods
4.1. Chemicals
DMEM/Ham’s F-12 medium (1:1) with phenol red, phosphate-buffered saline (PBS) Ca2+/Mg2+-free,
Trypsin, bovine serum albumin (BSA), antibiotics, and all reagents for the western blot were obtained
from Sigma Aldrich (St. Louis, MO, USA). Fetal calf serum was obtained from Gibco® (US).
2-mercaptoethanol was obtained from Life Technologies, Inc. Laboratories (Grand Island, NY,
USA). Hydrogen peroxide (H2O2), phosphodiesterase type 5 inhibitor (PDE5i), sildenafil citrate
salts (S) (98%), and secondary antibodies were purchased from Sigma Aldrich/Merck (Darmstadt,
Germany). All reagents for SDS-PAGE were from Santa Cruz (California, USA) and Cell Signaling
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(Leiden, The Netherlands). For RNA extraction, the TRIzol RNA isolation reagent was purchased
from Ambion™; for reverse transcription, 10 mM dNTP Mix, random primers, RNaseOUTNAse™,
ribonuclease inhibitor, DNase I® and SuperScript® III Reverse were purchased from Invitrogen. SYBR®
Green PCR Master Mix for qPCR was purchased from Life Technologies™ (Applied Biosystems®,
Waltham, MA, USA). Plastic ware for cell cultures and disposable filtration units for growth media
preparation were purchased from Corning (Milan, Italy).
4.2. Cell Cultures and Treatments
Human dermal fibroblasts (Hfb) were isolated from excisional skin biopsies from three patients
with early diffuse cutaneous SSc (dcSSc) (mean age 61.9 ± 9.2) and three healthy controls (mean age
55.6 ± 8.0) at the SSc clinic within the Leeds Institute of Rheumatic and Musculoskeletal Medicine (UK)
and processed as previously described [23]. Informed consent was obtained and approved by the
National Research Ethics Service (NRES) Committee (REC 10/H1306/88). Unless otherwise indicated, all
cells were treated for 24 h with H2O2 (100 µM) in the presence or absence of a pre-treatment of sildenafil
(1 µM) by adding it to the culture medium 30 min before treatment with hydrogen peroxide. The H2O2
concentration was selected after dose-response experiments to evaluate cell survival (data not shown).
The sildenafil concentration was selected on the basis of the near-therapeutic doses used to treat
erectile dysfunction, according to its pharmacokinetics (Cmax and area under the time–concentration
curves, AUC).
4.3. Cytokine Secretion Assay
Healthy and SSc fibroblasts were plated at 2 × 104 cells/mL in 96-well tissue culture plates. Cell
culture supernatants were assayed for IL-6 and IL-8 by magnetic bead-based multiplex assay according
to the manufacturer’s protocol. Data acquisition was performed by a Bio-Plex 200 System™ (Bio-Rad
Laboratories, Inc., Hercules, CA, USA), which uses Luminex fluorescent bead-based technology. Data
analysis was performed by Bio-Plex Manager™ 6.0 software (Bio-Rad Laboratories, Hercules, CA,
USA). Cell supernatants were run in triplicate.
4.4. RNA Extraction, Reverse Transcription, and Real-Time Quantitative PCR
Total RNA was obtained from ≈3.5 × 104 cells using TRIZOL according to the manufacturer’s
instructions and as previously described [24]. Treatment with DNAse enzyme was performed to
remove genomic DNA contamination. cDNA was obtained by reverse transcription of 500 ng of
total RNA. RT-qPCRs were performed as previously described [25–27]. Fluorescence intensities were
analyzed using the manufacturer’s software (7500 Software v2.05), and relative amounts were evaluated
using the 2−∆Ct method and normalized for ß-actin. Data are expressed as fold increases. Sequences
of primers for RT-PCR analysis:
IL-6 Fw: 5′-TTCGGTACATCCTCGACGGC-3′ and Rev: 5′-TCTGCCAGTGCCTCTTTGCT-3′; IL-8
Fw: 5′-TCCTGATTTCTGCAGCTCTGTG-3′ and Rev: 5′-CTGAACCCCAAGGCCAAC-3′; β-actin Fw:
5′-CTGAACCCCAAGGCCAAC-3′and Rev: 5′-AGCCTGGATAGCAACGTACA-3′.
4.5. Protein Expression Analysis
Healthy and SSc fibroblasts pre-treated with or without sildenafil (1 µM) and then stimulated
for 1 h with 100 µM H2O2 were lysed in RIPA buffer (150 mM NaCl, 50 mM tris-HCl pH 8, 1 mM
EDTA, 1% NP40, 0.25% sodium deoxycholate, 0.1% SDS, water to volume) supplemented with
protease and phosphatase inhibitor cocktails (Sigma–Aldrich, Darmstadt, Germany). As previously
described [28–30], for the immunoblot analysis, an equal amount of proteins (20–30 µg) was resolved
in SDS-polyacrylamide (BIO-RAD) gels (10–12%) and transferred onto nitrocellulose membranes
(Amersham, Little Chalfont, UK). Thereafter, membranes were incubated with primary antibodies
appropriately diluted in Tween Tris-buffered saline (TTBS). Proteins were revealed by the enhanced
chemiluminescence system (ECL plus; Millipore). Image acquisition was performed with Image Quant
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Las 4000 software (GE Healthcare, Chicago, IL, USA) and densitometric analysis with Quantity One®
software (Bio-Rad laboratories Inc.). Antibodies utilized were: p-STAT3 (Tyr705), STAT3, p-NF-κB
(Ser536) from Cell Signaling; p-AKT (Ser473), AKT, NF-κB, p-ERK1/2 (Thr 44/42), ERK, β actin from
Santa Cruz.
4.6. Statistical Analysis
All data were generated through experimental triplicates and are represented as the
mean ± standard error of the mean (SEM) or as fold increases vs. untreated cells. Protein and
mRNA contents were analyzed by one- or two-way ANOVA with Bonferroni’s correction for pair-wise
comparisons. Where necessary, a t-test analysis was performed. GraphPad Prism 8.0 (La Jolla, CA,
USA) was used for all statistical analyses, with significant differences determined by p value < 0.05.
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